Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.
Hologic Inc (HOLX) delivers innovative healthcare solutions through diagnostic imaging systems and surgical technologies focused on women’s health. This dedicated news hub provides investors and industry professionals with essential updates directly from the company and verified sources.
Access timely Hologic press releases, earnings reports, and strategic announcements in one centralized location. Track developments across key business segments including diagnostic systems, breast health technologies, and minimally invasive surgical solutions. Our curated feed ensures you never miss regulatory filings, product approvals, or partnership announcements impacting this medical technology leader.
This resource serves as your primary source for monitoring Hologic’s advancements in healthcare diagnostics and operational milestones. Content is rigorously verified to maintain factual accuracy while avoiding speculative analysis. Bookmark this page for efficient tracking of HOLX’s progress in developing technologies that enhance clinical decision-making worldwide.
Hologic (NASDAQ: HOLX) has announced its upcoming presentation at the 43rd Annual J.P. Morgan Healthcare Conference scheduled for Tuesday, January 14, 2025, at 1:30 p.m. Pacific Time. The event will feature both a presentation and Q&A session, which will be accessible through a live webcast.
Interested parties can access the webcast through a link on the Investors section of Hologic's website at http://investors.hologic.com. The webcast recording will remain available for 30 days after the event. Hologic is known for its focus on improving women's health and well-being through early detection and treatment technologies.
Hologic (NASDAQ: HOLX) has scheduled the release of its first quarter fiscal 2025 financial results for Wednesday, February 5, 2025, after market close. The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results.
Participants can join the call by dialing (888) 394-8218 in the US and Canada or +1 (773) 305-6853 for international callers, using access code 4103504. A webcast replay will be available on the company's investor relations website for 30 days following the call.
Hologic (HOLX) has completed its previously announced acquisition of Gynesonics, a private medical device company, for approximately $350 million. The acquisition brings the Sonata System into Hologic's portfolio, expanding their range of minimally invasive solutions for heavy periods and fibroids.
The Sonata System is a technology for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids. It combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation in an incisionless procedure. The system has already been used to treat thousands of women, according to Gynesonics' CEO Skip Baldino.
Hologic (NASDAQ: HOLX) has entered into an agreement with the CDC to develop analyte specific reagents (ASRs) for detecting H5N1 bird flu. The development comes as H5N1 continues to spread among wild birds, causing outbreaks in poultry and dairy cows in the U.S. The ASRs will be developed on the Panther Fusion® system, with over 1,700 systems installed across U.S. laboratories.
While Hologic doesn't currently plan to commercialize these ASRs, future commercialization may be considered if rapid H5N1 testing becomes necessary. The Panther systems can generate over 1,000 results in 24 hours and can quickly scale up testing capacity. This initiative builds on Hologic's diagnostic solutions portfolio, including their successful COVID-19 testing programs which shipped over 68 million tests to 40 countries in 2020.
Hologic (HOLX) has responded to the United States Preventive Services Task Force (USPSTF) draft guidelines for cervical cancer screening. The company emphasizes the importance of combining Pap and HPV testing as the gold standard for cervical cancer detection. Cervical cancer mortality rates have decreased by 70% due to screening programs, though incidence rates have plateaued and disproportionately affect Black and Hispanic women.
Multiple studies show that screening women ages 30-65 with combined Pap and HPV testing identifies more cervical pre-cancer and cancer than single tests. The draft guidelines support three screening strategies, including Pap testing for women ages 21-29, and maintain flexibility for shared decision-making between healthcare providers and patients.
Hologic (HOLX) announced the election of Dr. Martin Madaus to its Board of Directors, effective December 6, 2024. Dr. Madaus brings over 30 years of diagnostics and life sciences industry experience to the board. He currently serves as an Operating Executive at the Carlyle Group, which he joined in February 2019.
Dr. Madaus previously held positions as Chairman and CEO of Ortho Clinical Diagnostics, and served as Chairman, President and CEO of Millipore until its acquisition by Merck KGaA in 2010. He will serve on both the Compensation Committee and the Nominating and Corporate Governance Committee.
Four new studies about the Breast Cancer Index (BCI) test will be presented at the 2024 San Antonio Breast Cancer Symposium. The main study investigates BCI's potential to identify postmenopausal women with HR+ early-stage breast cancer who have minimal risk of distant recurrence.
The research validated an adjusted BCI prognostic model that identified a 'minimal risk' group with less than 5% 10-year distant recurrence risk. In the Stockholm and NCR studies, 20% and 16% of patients were identified as minimal risk, with 10-year distant recurrence risks of 2.3% and 4.5%, respectively.
The BCI test is currently recognized by NCCN and ASCO guidelines as the only test predicting which HR+ early-stage breast cancer patients may benefit from extended endocrine therapy beyond five years.
Hologic (NASDAQ: HOLX) presented new research demonstrating its Genius AI Detection 2.0 software performs consistently across diverse patient populations. The study evaluated over 7,500 digital breast tomosynthesis cases from women of different racial/ethnic backgrounds, showing similar performance across all groups. The company also announced the introduction of its next-generation Genius AI Detection PRO solution for the U.S. market, featuring improved accuracy, efficiency, and advanced capabilities including deep-learning algorithms, intuitive scoring, and an all-in-one interface with breast density scoring.
Hologic (NASDAQ: HOLX) will showcase new breast health technologies at RSNA 2024 in Chicago, December 1-5. The company will unveil the Envision™ Mammography Platform, featuring a 2.5-second scan time and tilt positioning for enhanced patient comfort. Additionally, Hologic will introduce its Genius AI® Detection PRO solution, an advanced cancer screening technology that improves accuracy and efficiency through deep-learning algorithms.
The company will present study results showing their AI Detection 2.0 software performs consistently across diverse patient populations. At Booth #1919, Hologic will display their complete portfolio of breast imaging and surgery solutions, including recently acquired Endomag wireless breast surgery localization products.
Hologic (HOLX) has announced its participation in three upcoming investor conferences. The company will present at the 2024 Stephens Annual Investment Conference in Nashville on November 21st at 10 a.m. CT, the 7th Annual Evercore ISI HealthCONx Conference in Coral Gables on December 3rd at 2:10 p.m. ET, and Citi's 2024 Global Healthcare Conference in Miami on December 4th at 8:45 a.m. ET. All presentations will be accessible via webcast through Hologic's investor relations website for 30 days following each event.
